Regorafenib: From bench to bedside in colorectal cancer

Expert Review of Clinical Pharmacology

Volumn 6, Issue 3, 2013, Pages 243-248

  Shahda, Safi ^a   Saif, Muhammad Wasif ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

angiogenesis; colorectal cancer; regorafenib; targeted therapy; VEGF

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BRIVANIB; CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FIRTECAN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NINTEDANIB; OXALIPLATIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; RAMUCIRUMAB; REGORAFENIB; SEMAXANIB; SORAFENIB; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB;

ABDOMINAL PAIN; ADENOID CYSTIC CARCINOMA; ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ASTHMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TARGETING; FATIGUE; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; LIVER CELL CARCINOMA; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; SKIN EXFOLIATION; SOLID TUMOR; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; PHENYLUREA COMPOUNDS; PYRIDINES; TREATMENT OUTCOME;

EID: 84877604650     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.13.11     Document Type: Review

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J. Clin. 62(5), 283-298 (2012).
2. Zauber AG, Winawer SJ, O'Brien MJ et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N. Engl. J. Med. 366(8), 687-696 (2012).
3. Benson AB 3rd, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22(16), 3408-3419 (2004).
4. Colucci G, Gebbia V, Paoletti G et al.; Gruppo Oncologico Dell'Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J. Clin. Oncol. 23(22), 4866-4875 (2005).
5. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J. Clin. Oncol. 26(21), 3523-3529 (2008).
6. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol. 19(8), 2282-2292 (2001).
7. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229-237 (2004).
8. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a Phase III randomised controlled trial. Lancet 370(9582), 135-142 (2007).
9. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357(20), 2040-2048 (2007).
10. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
11. Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25(13), 1658-1664 (2007).
12. Ellis LM. Angiogenesis and its role in colorectal tumor and metastasis formation. Semin. Oncol. 31(6 Suppl. 17), 3-9 (2004).
13. Maeda K, Chung YS, Takatsuka S et al. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J. Clin. Oncol. 13(2), 477-481 (1995).
14. Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann. Surg. 222(6), 695-699 (1995).
15. Fox SH, Whalen GF, Sanders MM et al. Angiogenesis in normal tissue adjacent to colon cancer. J. Surg. Oncol. 69(4), 230-234 (1998).
16. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423), 841-844 (1993).
17. Connolly DT, Heuvelman DM, Nelson R et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84(5), 1470-1478 (1989).
18. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc. Res. 14(1), 53-65 (1977).
19. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
20. Giantonio BJ, Catalano PJ, Meropol NJ et al.; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007).
21. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 20, 1842-1847 (2009).
22. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499-3506 (2012).
23. Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129(1), 245-255 (2011).
24. Mross K, Frost A, Steinbild S et al. A Phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin. Cancer Res. 18(9), 2658-2667 (2012).
25. Shimizu T, Tolcher AW, Patnaik A et al. Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors. J. Clin. Oncol. 28(15 Suppl.), Abstract 3035 (2010).
26. Strumberg D, Scheulen ME, Schultheis B et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a Phase I study. Br. J. Cancer 106(11), 1722-1727 (2012).
27. Hedbom S, Steinbild S, Frost A et al. Phase I study of BAY 73-4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumors. J. Clin. Oncol. 25(18 Suppl.), Abstract 3593 (2007).
28. Schultheis B, Folprecht G, Kuhlmann J et al. Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer. J Clin Oncol 29(15 Suppl.), Abstract 3585 (2011).
29. Grothey A, Van Cutsem E, Sobrero A et al.; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 303-312 (2013).
30. Kupsch P, Henning BF, Passarge K et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin. Colorectal Cancer 5(3), 188-196 (2005).
31. Azad N, Dasari A, Arcaroli J et al. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Invest. New Drugs 31(2), 345-354 (2013).
32. Starling N, Vázquez-Mazón F, Cunningham D et al. A Phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Ann. Oncol. 23(1), 119-127 (2012).
33. Sweeney CJ, Chiorean EG, Verschraegen CF et al. A Phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J. Clin. Oncol. 28(29), 4513-4520 (2010).
34. Qvortrup C, Jensen BV, Jorgensen TL, Nielsen D, Bjerregaard JK, Pfeiffer P. Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. Acta Oncol. 49(6), 833-836 (2010).
35. Saltz LB, Rosen LS, Marshall JL et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol. 25(30), 4793-4799 (2007).
36. Sharma S, Abhyankar V, Burgess RE et al. A Phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann. Oncol. 21(2), 297-304 (2010).
37. Gotlieb WH, Amant F, Advani S et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a Phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 13(2), 154-162 (2012).
38. Lockhart AC, Rothenberg ML, Dupont J et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J. Clin. Oncol. 28(2), 207-214 (2010).
39. Spratlin JL, Cohen RB, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 28(5), 780-787 (2010).
40. Chen E, Jonker D, Gauthier I et al. Phase I study of cediranib in combination with oxaliplatin and infusional 5-fluorouracil in patients with advanced colorectal cancer. Clin. Cancer Res. 15(4), 1481-1486 (2009).
41. Robertson JD, Botwood NA, Rothenberg ML, Schmoll HJ. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin. Colorectal Cancer 8(1), 59-60 (2009).
42. Garrett CR, Siu LL, El-Khoueiry A et al. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br. J. Cancer 105(1), 44-52 (2011).
43. Saunders MP, Wilson R, Peeters M et al. Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study. Cancer Chemother. Pharmacol. 64(4), 665-672 (2009).
44. Michael M, Gibbs P, Smith R, Godwood A, Oliver S, Tebbutt N. Open-label Phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest. New Drugs 27(3), 253-261 (2009).
45. Bouche O, Maindrault-Goebel F, Ducreux M et al. Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. Anticancer Res. 31(6), 2271-2281 (2011).
46. Mross K, Stefanic M, Gmehling D et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin. Cancer Res. 16(1), 311-319 (2010).
47. Poindessous V, Ouaret D, El Ouadrani K et al. EGFR-and VEGFR-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin. Cancer Res. 17(20), 6522-6530 (2011).
48. Lockhart AC, Cropp GF, Berlin JD et al. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Am. J. Clin. Oncol. 29(2), 109-115 (2006).
49. Tyagi P. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin. Color. Cancer 5, 24-26 (2005).